Table 2.
Twenty-Four CPR, Adipocyte Size, Adipocyte 11β-HSD Activity, and DEXA and MRS Parameters of Patients at Baseline and Months 1 and 3
| LGH (n = 8) |
Placebo (n = 9) |
|||||
|---|---|---|---|---|---|---|
| Baseline | Month 3 | δMonth 3 − Baseline | Baseline | Month 3 | δMonth 3 − Baseline | |
| Twenty-four-hour CPR, mg/d | 36.3 (9.5) | 35.9 (10.7) | −0.4 (3.4) | 25.9 (5.3) | 23.0 (5.2) | −2.9 (2.6) |
| Adipocyte size | ||||||
| Adipocyte diameter, μm | 102.0 (4.4) | 103.0 (1.5) | 1.0 (4.3) | 93.9 (5.7) | 96.4 (5.1) | 2.5 (6.4) |
| Adipocyte volume, cm3 | 56.7 (6.9) | 57.3 (2.4) | 0.6 (6.5) | 45.7 (8.0) | 48.8 (7.6) | 3.0 (10.0) |
| Adipocyte 11β-HSD activity, pmol/mg·h × 10−3 | ||||||
| Conversion of cortisone to cortisol | 3.2 (0.5) | 5.6 (1.2) | 2.4 (1.4) | 10.1 (2.5) | 5.6 (0.6) | −4.5 (2.6) |
| Conversion of cortisol to cortisone | 2.2 (0.5) | 3.4 (1.1) | 1.8 (1.6) | 1.9 (0.2) | 2.4 (0.3) | 0.4 (0.5) |
| DEXA studies | ||||||
| Total fat mass, kg | 38.9 (4.9) | 38.4 (5.4) | 0.47 (0.73) | 38.4 (6.6) | 37.3 (7.7) | 0.49 (0.80) |
| Total lean body mass, kg | 58.0 (7.1) | 56.3 (8.0) | 0 (1.11) | 57.7 (5.9) | 59.1 (7.0) | 1.57 (0.59) |
| Total fat, % | 39.2 (3.2) | 39.7 (3.5) | 0.43 (0.46) | 36.9 (3.1) | 35.5 (3.3) | −0.39 (0.42) |
| MRS studies, % of water peak | ||||||
| IHL | 11.8 (6.5) | 10.7 (9.3) | 2.9 (2.7) | 12.5 (6.3) | 11.4 (5.5) | −1.1 (1.1) |
| EMCL | 4.7 (1.6) | 5.8 (2.3) | 0.7 (0.6) | 2.8 (0.4) | 3.4 (0.9) | 0.7 (0.4) |
| IMCL | 2.0 (0.6) | 1.7 (0.4) | 0.1 (0.4) | 1.2 (0.2) | 0.9 (0.2) | −0.2 (0.1) |
Data are presented as mean (SE). Comparisons of all data within groups (month 3 vs baseline) and between groups (LGH vs placebo of δmonth 3 − baseline) were all not significant.